PharmaResearch Co Ltd
KOSDAQ:214450
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89 100
235 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
PharmaResearch Co Ltd
Cost of Revenue
PharmaResearch Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cost of Revenue
-₩85.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cost of Revenue
-₩1.5T
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cost of Revenue
-₩227.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Cost of Revenue
-₩1.2T
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cost of Revenue
-₩85.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cost of Revenue
-₩56.3B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
PharmaResearch Co Ltd
Glance View
PharmaResearch Co., Ltd. engages in the research and development of refined raw materials for cell and tissue regeneration through marine bio technology. The company is headquartered in Gangneung, Gangwon-Do. The company went IPO on 2015-07-24. The firm produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The firm mainly provides its products in domestic market.
See Also
What is PharmaResearch Co Ltd's Cost of Revenue?
Cost of Revenue
-85.6B
KRW
Based on the financial report for Jun 30, 2024, PharmaResearch Co Ltd's Cost of Revenue amounts to -85.6B KRW.
What is PharmaResearch Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%
Over the last year, the Cost of Revenue growth was -47%. The average annual Cost of Revenue growth rates for PharmaResearch Co Ltd have been -29% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
